TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02108561

Intervention type: OTHER
Intervention: Post Surgical Her2 testing
Description: Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
Study: NCT04422600

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The investigators will then correlate that exposure with neurodevelopmental outcomes.

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The investigators will then correlate that exposure with neurodevelopmental outcomes.
Study: NCT03502265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otteroo
Description: Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
Study: NCT04126200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study: NCT02019875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: CYP3A4 and Pgp inhibitor in both intestine and liiver
Study: NCT04126200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: feladilimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: feladilimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.
Study: NCT01992185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photocil for Vitiligo
Description: Photocil for Vitiligo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sunscreen (SPF 2)
Description: Placebo - Sunscreen (SPF 2)
Study: NCT01043887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: single oral dose administration 10 mg ridaforolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: single oral dose administration 10 mg ridaforolimus
Study: NCT01458353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Description: Stapled anastomosis after ileocolonic resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handsewn anastomosis
Description: Handsewn anastomosis after ileocolonic resection
Study: NCT02071030

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Third molar removal
Description: Surgically removing the third molar in the lower jaw

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Third molar removal
Description: Surgically removing the third molar in the lower jaw
Study: NCT02019875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: CYP3A4 and Pgp inhibitor in both intestine and liiver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Description: CYP3A4 inhibitor in intestine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice
Description: CYP3A4 inhibitor in intestine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03274518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expanded Hemodialysis
Description: Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online Hemodiafiltration
Description: Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis.
Study: NCT00147303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-9042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-9042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-9042
Study: NCT00692419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom management nurse intervention
Description: A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
Study: NCT04062383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
Study: NCT00403845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT00954642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNRP1685A
Description: Escalating intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNRP1685A
Description: Escalating intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study: NCT00692419

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback intervention
Description: Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
Study: NCT03515642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT group
Description: Physical Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIIT group
Description: Physical Training
Study: NCT03684382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeW-I group
Description: A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
Study: NCT00403845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT01628965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT04126200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.
Study: NCT01423266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 12-week supervised weight loss intervention
Description: Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 12-week supervised weight loss intervention
Description: Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
Study: NCT03298763

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MSCTRAIL
Description: 3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: MSCTRAIL
Description: 3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
Study: NCT01029847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
Study: NCT00527904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400 (VIMOVO)
Description: 500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
Study: NCT00403845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT04126200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered.
Study: NCT00403845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT00028600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC \>= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC \> 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ cells
Description: 2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
Study: NCT01122615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
Study: NCT00761202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®
Description: Eyedrops as required, but at least 3 times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate
Description: Eyedrops as required, but at least 3 times per day
Study: NCT00028600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
Study: NCT03343483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteering
Description: Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Review
Description: Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
Study: NCT00028600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 200mg/sq m IV infusion over 15-30 min D 2 auto transpl
Study: NCT01835743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia HPS Laser
Description: The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
Study: NCT00028600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: 0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
Study: NCT04351243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimsilumab
Description: Gimsilumab is a fully human monoclonal antibody (mAb).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03985371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDTA Eye Drops
Description: One drop in the Band Keratopathy affected eye only, two times per day for six months.
Study: NCT04232111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat
Description: Heat applied to hand

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat
Description: Heat applied to hand

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum
Description: vacuum applied to hand

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: neither heat nor vacuum
Study: NCT04477655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Description: Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Description: Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%